33172-54-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-hydroxy-5-methyl-benzaldehyde is used as a reagent for the preparation of flavone derivatives, which are essential in the treatment and prophylaxis of hepatitis B virus disease. 3-BROMO-2-HYDROXY-5-METHYL-BENZALDEHYDE plays a crucial role in the synthesis of these therapeutic agents, contributing to the development of effective medications against hepatitis B.

Upstream product

• 50-00-0 formaldehyd 
• 106-44-5 p-cresol 
• 67-66-3 chloroform 
• 6627-55-0 2-bromo-p-cresol 
• 60-29-7 diethyl ether 
• 7726-95-6 bromine 
• 613-84-3 2-hydroxy-5-methylbenzaldehyde 

Downstream Products

• 1000414-97-0 N-(3-bromo-5-methylsalicylidene)-3-[bis(5-methyl-2-furyl)methyl]aniline 
• 1247212-14-1 8-bromo-6-methyl-3-phenylcoumarin 
• 1247212-20-9 8-bromo-6-methyl-3-(3,5-dimethoxyphenyl)coumarin 
• 1247212-21-0 8-bromo-6-methyl-3-(3,4,5-trimethoxyphenyl)coumarin 
• 708209-60-3 C₂₂H₂₄Br₂N₂O₂ 
• 1032506-48-1 2-bromo-6-cyano-4-methylphenol 

Relevant academic research and scientific papers

Facile one-pot transformation of phenols into o-cyanophenols

The treatment of phenols with paraformaldehyde in the presence of MgCl2 and Et3N in THF at 80 C, followed by reaction with molecular iodine and aq. ammonia at room temperature provided the corresponding o-cyanophenols in moderate to good yields. The present reaction is a one-pot transformation of phenols into o-cyanophenols using much less expensive reagents than are typically used; the reaction is free of both transition-metals and cyanide. The utility of this reaction was highlighted during our preparation of Febuxostat from p-bromophenol.

Regioselective synthesis of bromo-substituted 3-arylcoumarins

Regioselective syntheses of 3-arylcoumarins possessing a bromine substituent either on the 3-aryl ring, the coumarin moiety or on a lateral chain of a coumarin is reported. The regioselectivity is influenced by the substituents present in the substrates.

New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors

With the aim to find out the structural features for the MAO inhibitory activity and selectivity, in the present communication we report the synthesis and pharmacological evaluation of a new series of bromo-6-methyl-3- phenylcoumarin derivatives (with bro

(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.

Ligand tuning in the chromium-salen-mediated asymmetric epoxidation of alkenes

A series of Cr(salen) complexes have been synthesised from 5-substituted-3-bromosalicylaldehydes and trans-1,2-cyclohexanediamine. These have been used to probe the Cr(salen)-mediated asymmetric epoxidation of alkenes. No simple correlation was found between the electronic character of the salen-substituents and the enantioselectivity - multiple oxidation pathways are proposed as a possible explanation. Enantioselectivities of up to 90% have been achieved using a novel, synthetically accessible Cr(salen) complex.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

Development of serine protease inhibitors displaying a multicentered short (<2.3 ?) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa

Novel scaffolds that bind to serine proteases through a unique network of short hydrogen bonds to the catalytic Ser195 have been developed. The resulting potent serine protease inhibitors were designed from lead molecule 2-(2-hydroxyphenyl)1H-benzoimidazo

Solid state nuclear bromination with N-bromosuccinimide. Part 2. Experimental and theoretical studies of reactions with some substituted benzaldehydes

N-Bromosuccinimide reacts with aromatic aldehydes in the solid state to yield exclusively nuclear brominated products while a similar reaction in the solution phase produces a number of products under varied conditions. The reactivity and regioselectivity have been studied in terms of the energies of HOMO, HOMO-LUMO difference, reaction free energy, reaction conditions and crystal packing. Single crystal X-ray structural analysis of 3,4-dihydroxybenzaldehyde has been carried out. Crystal packing energies of some of the reactive and unreactive benzaldehydes indicate the importance of molecular bromine diffusion in the solid state.